{Reference Type}: Journal Article
{Title}: Co expression of EGFR and CD10 in patients with phyllodes tumors of the breast: a single center experience in North Western Algeria.
{Author}: Belhadj A;Brikci SB;Akhrouf C;Belhadj A;Medjamia M;Sahraoui T;
{Journal}: Afr Health Sci
{Volume}: 23
{Issue}: 4
{Year}: 2023 Dec
{Factor}: 1.108
{DOI}: 10.4314/ahs.v23i4.29
{Abstract}: UNASSIGNED: Breast phyllodes tumors (BPT) have variable malignant potential, their histological classification remains insufficient for an accurate diagnosis.
UNASSIGNED: We attempted to investigate CD10 (Cluster of differentiation 10) and EGFR (Epidermal growth factor receptor) expression in BPT in order to highlight their diagnostic and prognostic values.
UNASSIGNED: Eight patients with BPT are recruited from January 2014 to December 2020 and immunohistochemical assessment of CD10 and EGFR is realized.
UNASSIGNED: Median age was 27±15.2, the mean tumor size was 9.63±10.21. Only malignant tumours showed expression for EGFR. Borderline and malignant tumors were CD10 positive. Patients overexpressing CD10 were postmenopausal with great tumor size, 25% of these were sarcomatous. Coexistence of CD10 and EGFR overexpression was found in 25% of cases and was associated with age (P=0.008), tumor size (P=0.030) and hitologic types (P=0.014). PC1 and PC2, were extracted, they accounted cumulatively for 94.7% of the variance of the data analysed, it suggests that patient's age and histological type of tumor have significant association with CD10 and EGFR expression in BPT.
UNASSIGNED: EGFR and CD10 overexpressed combined proteins in phyllode tumors constitute, with histopathological parameters, an important prognostic factor as well as a promising potential targets.